A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer

被引:99
作者
Mavroudis, D
Papadakis, E
Veslemes, M
Tsiafaki, X
Stavrakakis, J
Kouroussis, C
Kakolyris, S
Bania, E
Jordanoglou, J
Agelidou, M
Vlachonicolis, J
Georgoulias, V
机构
[1] Univ Crete, Sch Med, Dept Med Oncol, Iraklion, Greece
[2] Sotiria Gen Hosp Athens, Dept Pulm Dis 1, Athens, Greece
[3] Univ Athens, Sotiria Gen Hosp Athens, Sch Med, Dept Pulm Dis, Athens, Greece
[4] Sismanogl Gen Hosp Athens, Dept Pulm Dis 2, Athens, Greece
[5] Agios Savvas Anticanc Hosp Athens, Dept Med Oncol 1, Athens, Greece
[6] Univ Crete, Sch Med, Dept Biostat, Iraklion, Greece
关键词
cisplatin; etoposide; paclitaxel; randomized trial; small-cell lung cancer;
D O I
10.1023/A:1011131303391
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Previous phase I-II studies have shown that the combination of paclitaxel-cisplatin-etoposide (TEP) is very active and well tolerated in patients with small-cell lung cancer (SCLC). In order to compare the TEP combination to cisplatin-etoposide (EP) regimen as front-line treatment in patients with SCLC, we conducted a randomised multicenter study. Patients and methods: One hundred thirty-three chemotherapy-naive patients with histologically proven limited or extensive stage SCLC were randomised to receive either paclitaxel 175 mg/m(2) i.v. three-hour infusion on day 1 and cisplatin 80 mg/m(2) i.v. on day 2 and etoposide 80 mg/m(2) i.v. on days 2-4 with G-CSF support (5 mcg/kg s.c. days 5-15) or cisplatin 80 mg/m(2) i.v. on day 1 and etoposide 120 mg/m(2) i.v. on days 1-3 in cycles every twenty-eight days. Results: Due to excessive toxicity and mortality observed in the TEP arm, an early interim analysis was performed and the study was closed. Sixty-two patients received two hundred sixty-one cycles of TEP and seventy-one patients three hundred twenty-three cycles of EP. The two patient groups were well balanced for age, sex, performance status, stage of disease and the presence of abnormal LDH at diagnosis. In an intention-to-treat overall analysis both regimens were equally active with a complete and partial response rate of 50% (95% confidence interval (CI): 37.5%-62.4%) for TEP and 48% (95% CI: 36.2%-59.5%) for EP (P = 0.8). The median time to disease progression was 11 months for TEP and 9 months for EP (P = 0.02). The duration of response, one-year survival and overall survival were similar in the two arms. Similarly, in an intention-to-treat subgroup analysis of patients with limited or extensive stage disease, there was no difference in the activity between the two regimens except of a longer median time to disease progression in the extensive stage in favour of the TEP regimen, eight versus six months (P = 0.04). However, there were eight toxic deaths in the TEP arm versus none in the EP arm (P = 0.001). Moreover, the TEP regimen was associated with more severe toxicity than the EP regimen in terms of grade 4 neutropenia (P = 0.04), grade 3-4 thrombocytopenia (P = 0.02), febrile neutropenia (P = 0.08), grade 3-4 diarrhea (P = 0.01), grade 3-4 asthenia (P = 0.05) and grade 3 neurotoxicity (P = 0.06). Conclusions: In this early terminated study, the TEP regimen was significantly more toxic than the EP regimen. The TEP regimen is associated with significant toxicity and mortality, and should not be used outside of a protocol setting. For future investigations, dose and schedule modifications are necessary to reduce toxicity.
引用
收藏
页码:463 / 470
页数:8
相关论文
共 30 条
[1]  
Altman G. G, 1991, PRACTICAL STAT MED R
[2]  
[Anonymous], 1989, Analysis of binary data
[3]  
Armitage P, 1990, STAT METHODS MED RES
[4]  
Birch R, 1997, SEMIN ONCOL, V24, P135
[5]  
BONI C, 1989, CANCER, V63, P638, DOI 10.1002/1097-0142(19890215)63:4<638::AID-CNCR2820630406>3.0.CO
[6]  
2-8
[7]  
Bunn PA, 1997, SEMIN ONCOL, V24, P144
[8]  
Bunn PA, 1997, SEMIN ONCOL, V24, pS69
[9]   Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole [J].
Cottin, V ;
Arpin, D ;
Lasset, C ;
Cordier, JF ;
Brune, J ;
Chauvin, F ;
Trillet-Lenoir, V .
ANNALS OF ONCOLOGY, 1999, 10 (07) :809-815
[10]   PHASE-II STUDY OF PACLITAXEL IN PATIENTS WITH EXTENSIVE-DISEASE SMALL-CELL LUNG-CANCER - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY [J].
ETTINGER, DS ;
FINKELSTEIN, DM ;
SARMA, RP ;
JOHNSON, DH .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1430-1435